Physician profile
Daniel Chiu
NPI 1427419530
$16,651.61
in general payments reported to CMS, 2019-2025
39 companies · $3,584 in 2025
The $3,584 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,362 · 2022: $3,600 · 2023: $3,440 · 2024: $3,666 · 2025: $3,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,589.31 |
| Education | $100.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,952.77 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,822.29 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,598.57 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,181.96 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $730.63 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $601.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $561.52 | 2022-2025 | |
| Ardelyx, INC. | $504.83 | 2022-2025 | Ibsrela |
| Pfizer INC. | $500.02 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $369.27 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $358.58 | 2023-2025 | Voquezna |
| Celgene Corporation | $346.90 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $335.99 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $329.31 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $286.89 | 2021-2025 | Linzess |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $281.60 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.89 | 2023-2024 | Cyltezo |
| Redhill Biopharma INC. | $174.24 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Daiichi Sankyo INC. | $158.73 | 2021-2022 | |
| Braintree Laboratories, INC. | $158.32 | 2021-2025 | Suflave, Sutab |
| Celltrion USA INC. | $149.98 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $127.63 | 2022-2023 | Rebyota |
| Lilly USA, LLC | $124.84 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $108.70 | 2022-2025 | Dupixent |
| Vivus LLC | $101.50 | 2024-2025 | Qsymia, Pancreaze |
| Amgen INC. | $91.52 | 2021 | |
| Albireo Pharma, INC. | $73.29 | 2024 | Iqirvo |
| Evoke Pharma, INC. | $68.26 | 2022-2023 | Gimoti |
| Alnylam Pharmaceuticals INC. | $66.07 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $55.66 | 2023-2024 | |
| Exact Sciences Corporation | $50.58 | 2024 | Cologuard Collection Kit |
| Axonics, INC. | $35.91 | 2024 | Axonics |
| Ipsen Biopharmaceuticals, INC | $32.70 | 2025 | Iqirvo |
| Biocon Biologics INC | $26.24 | 2025 | Hulio |
| Shield Therapeutics INC | $20.29 | 2022 | |
| Novo Nordisk INC | $18.75 | 2023 | |
| Intra-Sana Laboratories | $17.42 | 2021 | |
| W. L. Gore & Associates, INC. | $15.45 | 2022 | |
| Pinnacle Biologics, INC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.